Clinical trials · Raleigh–Durham, NC
Cancer clinical trials in Raleigh–Durham
We’re tracking 417 recruiting cancer studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Durham, North CarolinaAges 18 years+ - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Durham, North CarolinaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Durham, North CarolinaAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Durham, North CarolinaAges 21 years+ - NCT04294927Recruiting
Tube removal first, then ovaries later for high-risk women
This study looks at whether removing the fallopian tubes first, and the ovaries later, is safe for women with certain inherited gene mutations that raise ovarian cancer risk. It may help you understand a prevention approach when you’re considered high risk and have finished having children.
Durham, North CarolinaAges 25–50 - NCT05486572Recruiting
Ultrasound or MRI to help prevent liver cancer deaths
This study compares ultrasound scans versus MRI scans to see which one better helps prevent deaths from liver cancer in people with cirrhosis. You may be assigned to one of the two imaging tests and follow-up visits to track whether liver cancer develops or is caught early.
Durham, North CarolinaAges 18–75 - NCT04379596RecruitingPhase 2
Testing T-DXd combinations for HER2 stomach or esophagus cancer
This Phase 2 study tests how safe and effective T-DXd (an anti-cancer medicine) is in combination for people with advanced stomach/GEJ/esophagus cancer that is HER2-positive or HER2-low. It may help people whose cancer has spread or cannot be removed, depending on their prior treatments and test results.
Durham, North CarolinaAges 18–130 - NCT07507643RecruitingPhase 3
Steroid treatment before liver surgery study
This study tests if a steroid called methylprednisolone can help people recovering from major liver surgery. It aims to see if it reduces inflammation and improves outcomes.
Durham, North CarolinaAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Durham, North CarolinaAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Durham, North CarolinaAges 18 years+ - NCT06708949RecruitingPhase 2
Immunotherapy combo for advanced kidney cancer
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
Durham, North CarolinaAges 18 years+ - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Durham, North CarolinaAges 2–21 - NCT04107181Recruiting
Speculum-free screening for cervical cancer testing
This pilot study tests a new way to check for cervical cancer that does not use a speculum (a tool used during pelvic exams). If you qualify, you may be offered this alternative screening method as part of the study.
Durham, North CarolinaAges 21–65 - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Durham, North CarolinaAges 18 years+ - NCT06710548Recruiting
REVITALIZE: Reducing Fatigue in Ovarian Cancer on PARP Inhibitors
This study tests whether a program called REVITALIZE can help reduce severe fatigue in women with ovarian cancer who are currently taking a PARP inhibitor (a type of targeted therapy). The goal is to see if this approach improves daily energy and quality of life.
Durham, North CarolinaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Durham, North CarolinaAges 12 years+ - NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Durham, North CarolinaAges 12 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Durham, North CarolinaAges 18 years+ - NCT04038502RecruitingPhase 2
Testing carboplatin or olaparib for gene-linked prostate cancer
This Phase 2 study tests whether carboplatin or olaparib can help people with prostate cancer that has certain DNA repair gene changes. It’s designed for advanced (metastatic) prostate cancer that is growing despite standard hormone-blocking treatment.
Durham, North CarolinaAges 18 years+ - NCT06371768Recruiting
Helping Young Cancer Survivors Manage Symptoms & Transition to Care
This study is designed to help adolescent and young adult cancer survivors manage symptoms and smoothly transition to post-treatment care. If you finished treatment for certain cancers within the past 1 to 5 years, you may be able to join.
Durham, North CarolinaAges 18–39 - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Durham, North CarolinaAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Durham, North CarolinaAges 18 years+ - NCT06952504RecruitingPhase 3
Comparing two drug combos for advanced endometrial cancer
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
Durham, North CarolinaAges 18 years+ - NCT05879211Enrolling by invitation
Care learning lab for Duke Health patients
This trial is a “learning laboratory” that studies how best to provide goal-focused care. It may help improve care experiences for Duke Health patients, based on what the study learns.
Durham, North CarolinaAges 18 years+
Hear when a new Cancer trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 10 studies
- Duke Cancer Institute · 4 studies
- Duke University · 4 studies
- Duke Cancer Center · 3 studies
- Durham VA Medical Center · 3 studies
- UNC Lineberger Comprehensive Cancer Center · 2 studies
- Duke University Health System
- Research Site
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in North Carolina.
Common questions
- Are there cancer clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 417 recruiting cancer studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.